A Single Dose Safety, Tolerability, Pharmacokinetic and Food Effect Study of KVD900 (Sebetralstat) in Healthy Volunteers

Inclusion Criteria: * Healthy male subjects between 18 and 55 years of age. * Healthy subjects as determined by past medical history and as judged by the Chief Investigator or designee. * Male subject willing to use a highly effective method of contraception. * Subject with a body mass index (BMI) of 18-32 kg/m2. * Subject with no clinically significant history of previous allergy or sensitivity to KVD900 or any of the excipients contained within the investigational medicinal product (IMP). * Subject with no clinically significant abnormal serum biochemistry, haematology, clotting profiles, and urine examination values within 28 days before the first dose of IMP. * Subject with a negative urinary drugs of abuse screen, determined within 28 days before the first dose of IMP * Subject with negative human immunodeficiency virus (HIV) and hepatitis B surface antigen (Hep B) and hepatitis C virus antibody (Hep C) results. * Subject with no clinically significant abnormalities in 12-lead electrocardiogram * Subjects must not donate sperm from first dose until at least 3 months after last dose of IMP. * Subjects without any special food restrictions that would hinder ability to consume the high fat breakfast provided during study Part C; such as lactose intolerance , vegan, low-fat, low sodium, etc. * Subjects with no known allergy or sensitivity to lactose and/or any additional excipients contained in IMP. * Subject must be available to complete the study (including all follow up visits). * Subject must satisfy the Chief Investigator or designee about their fitness to participate in the study. * Subject must provide written informed consent to participate in the study. Exclusion Criteria: * A clinically significant history of gastrointestinal disorder likely to influence IMP absorption. * Use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements . * Evidence of renal, hepatic, central nervous system, respiratory, cardiovascular (no history of syncope or vasovagal events), or metabolic dysfunction. * Subjects with a history of clotting abnormalities. * A clinically significant history of drug or alcohol abuse in the last 5 years. * Users of nicotine products i.e., current smokers or ex-smokers who have smoked within the 6 months prior to dosing with the study medication or users of cigarette replacements. * Inability to communicate well with Investigators. * Participation in a New Chemical Entity clinical study within the previous 3 months or a marketed drug clinical study within the 30 days before the first dose of IMP. * Donation of 450 mL or more blood within the 3 months before the first dose of IMP.